September results, Rs7 dividend and 1:1 bonus approved; record date November 7

Results RestatedResults View source PDF Explain this filing

LALPATHLAB · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+1.6%Reaction day

₹1545.00

prior close

₹1578.80

announcement price

In-mkt

timing

Nifty Smallcap 250market · index membership as recorded later (tracked since Jun 2026)-0.6%+2.2% vs market

Healthcare Service Provider peers, median of 22sector+0.0%+1.6% vs sector

On the reaction day the stock moved 2.2 pts more than Nifty Smallcap 250 and 1.6 pts more than its Healthcare Service Provider peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.3

10m

-0.5

15m

+1.4

30m

-1.2

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+1.6-0.6+2.2+0.0+1.6

Next day

+5.1+0.1+5.0+0.0+5.1

+2.4-0.5+3.0+0.0+2.4

+0.8-2.0+2.8-2.3+3.1

+0.3-2.2+2.5-3.0+3.3

-0.2-2.3+2.0-0.4+0.2

-0.2-1.7+1.5-0.2+0.1

15d

+0.9-4.6+5.5-1.6+2.6

-1.0-3.7+2.7-5.8+4.8

-4.0-4.2+0.2-7.2+3.2

-7.8-10.9+3.2-14.2+6.4

UpDownMarket · Nifty Smallcap 250Sector · Healthcare Service Provider peers, median of 22Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

The board approved unaudited consolidated and standalone results for the quarter and half year ended September 30, 2025. Standalone comparatives were restated after a business transfer from a subsidiary. It declared a second interim dividend of Rs7 per share, with November 7, 2025 as the record date and payment within 30 days. It also approved a 1:1 bonus issue of about 8.38 crore shares, subject to shareholder and regulatory approval.

Likely market impact

Dividend provides a cash return. The 1:1 bonus doubles share count without raising value per share. Shareholder and regulatory approvals are pending.